Topology of a human equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter (hENT1) implicated in the cellular uptake of adenosine and anti-cancer drugs.
about
A mild form of SLC29A3 disorder: a frameshift deletion leads to the paradoxical translation of an otherwise noncoding mRNA splice variantMutation of leucine-92 selectively reduces the apparent affinity of inosine, guanosine, NBMPR [S6-(4-nitrobenzyl)-mercaptopurine riboside] and dilazep for the human equilibrative nucleoside transporter, hENT1Molecular determinants of substrate selectivity of a novel organic cation transporter (PMAT) in the SLC29 familyThe clinically relevant pharmacogenomic changes in acute myelogenous leukemiaTransporters at CNS barrier sites: obstacles or opportunities for drug delivery?FUN26 (function unknown now 26) protein from saccharomyces cerevisiae is a broad selectivity, high affinity, nucleoside and nucleobase transporter.Blood brain barrier: a challenge for effectual therapy of brain tumorsBone marrow stromal cells modulate mouse ENT1 activity and protect leukemia cells from cytarabine induced apoptosisControl of glutamatergic neurotransmission in the rat spinal dorsal horn by the nucleoside transporter ENT1Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy.Equilibrative nucleoside transporters-A review.Second-site suppression of a nonfunctional mutation within the Leishmania donovani inosine-guanosine transporter.Role of transmembrane domain 4 in ligand permeation by Crithidia fasciculata equilibrative nucleoside transporter 2 (CfNT2).Transmembrane segment 11 appears to line the purine permeation pathway of the Plasmodium falciparum equilibrative nucleoside transporter 1 (PfENT1).Tyrosine 112 is essential for organic cation transport by the plasma membrane monoamine transporterMolecular biology and regulation of nucleoside and nucleobase transporter proteins in eukaryotes and prokaryotes.Nucleobase transport by human equilibrative nucleoside transporter 1 (hENT1).Looking to the future: biomarkers in the management of pancreatic adenocarcinoma.Purine import into malaria parasites as a target for antimalarial drug development.Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy.Lack of the nucleoside transporter ENT1 results in the Augustine-null blood type and ectopic mineralization.Nucleoside and nucleobase transporters in parasitic protozoa.The Role of Flexible Loops in Folding, Trafficking and Activity of Equilibrative Nucleoside Transporters.Purine and pyrimidine transport in pathogenic protozoa: from biology to therapy.Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug developmentConcentrative nucleoside transporters (CNTs) in epithelia: from absorption to cell signaling.Two novel nucleobase/pentamidine transporters from Trypanosoma bruceiGenetic factors influencing cytarabine therapy.Uptake carriers and oncology drug safety.Human nucleoside transporters: biomarkers for response to nucleoside drugs.Functional characterization of human equilibrative nucleoside transporter 1.Transporters that translocate nucleosides and structural similar drugs: structural requirements for substrate recognition.Nucleoside/nucleobase transporters: drug targets of the future?New insights into the synergism of nucleoside analogs with radiotherapyClinical potential of elacytarabine in patients with acute myeloid leukemia.An extensive pharmacokinetic, metabolic and toxicological review of elderly patients under intensive chemotherapy for acute myeloid leukemia.Equilibrative nucleoside transporter 1 expression in primary human hepatocytes is highly variable and determines uptake of ribavirin.Loops and layers of post-translational modifications of drug transporters.Pharmacogenomics and the treatment of acute myeloid leukemia.Identification of a novel point mutation in ENT1 that confers resistance to Ara-C in human T cell leukemia CCRF-CEM cells.
P2860
Q21090962-8EE7C916-E256-4C11-9A9B-DE3E6B6A27FDQ24530833-CFF7D9C8-DD9C-4643-BED1-C542192882CFQ24655176-21F15F7C-999F-48A7-82AF-0FF034AE9185Q27014790-A73FA517-A1A5-4D45-86A5-153A75D8F552Q27690256-8BE7E842-F02D-4AA4-8419-E501EB44F7D8Q27936958-EC1F97C3-74AC-41DC-A5D3-314CC4D73F48Q28081947-052E480A-10B9-408A-8443-0B341AB86D7FQ28483881-53DD4A34-0939-4F52-9AFF-901FEE0BDAF5Q28570116-D6DF99FB-2CC2-4AD4-BDDC-06AA422F0E79Q30238470-622938CB-392C-49E2-B641-2FC68DBE1ABFQ30244329-A775B16B-4322-4945-9EFE-CD87B992AA63Q33208191-FA9ECAFE-1120-41FF-BC67-4C310BA8A09EQ33673397-755A2F20-0168-4B14-8276-1F3AD96499F0Q33883226-B338CEAB-7835-4F38-A354-5BC14AA01121Q34367791-3D6FA80D-7EDB-41BE-A3FF-99FC43BCD2CDQ35003182-DCAA3F3E-D013-4E55-A155-75582AFE897BQ35213302-DA2469B5-3822-464D-8EF7-7E74F6F62D5BQ35297202-AA579349-BF35-41E3-8905-B2C7928A0C01Q35513431-7278E2DC-90C7-442C-B707-7E55776E000DQ35567292-5486B850-1447-4418-8815-07A662D15617Q35692423-3A9D4CAA-0D48-4E15-8CF2-E5F58D2D46D0Q35742322-4BC573A0-5A9A-4B8A-B04C-474D86029B22Q35788344-7F2AB125-C8F6-4723-9089-93E5605DEB0CQ36205383-4BB4E006-99F2-4D7E-9D9F-44CE84EB6C03Q36446094-74B3947B-2734-4B77-B528-53B7E5C28DFCQ36920475-68C77994-EE63-49E7-810A-6AA6048A3C0FQ37071492-E2C58D56-D688-43E7-90F1-3DDB76943F68Q37618228-FBE005C7-C123-4B73-96D3-1A5E860CF51EQ37663396-DB0FCC00-5607-4C11-8A9C-D1D9C0EC1DD4Q37698437-54DD5E5F-470C-459B-92C3-C7C5F7348D7BQ37712414-C599D8C8-8140-48F3-9C8E-F099CD36DD9CQ37834510-366BEE72-1B0F-414D-AE54-1396D7E62924Q37855808-7D57F525-0FBD-42FF-B211-5536E0DE39EAQ38143241-06C9711F-B381-47EA-9C78-6B44213CF0E8Q38282095-07523B6A-1949-482F-B761-F0A4BEDCBA18Q38285621-132A6F76-D120-4E4D-AC0A-3A754DB4FE82Q38707179-4F9D277E-8B52-4B87-8DAA-40C60665A1C5Q38833348-B5D0577C-7C3C-4259-A9AF-3F0A29E821CBQ38887034-AF25EEB6-97A7-4149-B289-4807EC1BD566Q39900095-8E6090EF-088C-497A-913D-924D84F8428D
P2860
Topology of a human equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter (hENT1) implicated in the cellular uptake of adenosine and anti-cancer drugs.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Topology of a human equilibrat ...... enosine and anti-cancer drugs.
@ast
Topology of a human equilibrat ...... enosine and anti-cancer drugs.
@en
Topology of a human equilibrat ...... enosine and anti-cancer drugs.
@nl
type
label
Topology of a human equilibrat ...... enosine and anti-cancer drugs.
@ast
Topology of a human equilibrat ...... enosine and anti-cancer drugs.
@en
Topology of a human equilibrat ...... enosine and anti-cancer drugs.
@nl
prefLabel
Topology of a human equilibrat ...... enosine and anti-cancer drugs.
@ast
Topology of a human equilibrat ...... enosine and anti-cancer drugs.
@en
Topology of a human equilibrat ...... enosine and anti-cancer drugs.
@nl
P2093
P2860
P356
P1476
Topology of a human equilibrat ...... enosine and anti-cancer drugs.
@en
P2093
Baldwin SA
Sundaram M
P2860
P304
45270-45275
P356
10.1074/JBC.M107169200
P407
P577
2001-10-02T00:00:00Z